Marquee Brands Enters Strategic Partnership With DAMAC Group for a Majority Interest in Roberto Cavalli
20.5.2026 21:30:00 EEST | Business Wire | Press release
Marquee Brands, the premier global brand management company and leading brand accelerator, today announced a definitive agreement for a majority interest in Roberto Cavalli, through a strategic partnership with DAMAC Group, the leading Dubai-based global conglomerate and luxury real estate developer. The transaction is expected to close in the second quarter of 2026, after which DAMAC Group will remain a significant shareholder. Founded in Florence in 1970, Roberto Cavalli the iconic luxury house celebrated for its avant-garde design and distinct Italian craftsmanship joins Marquee Brands’ portfolio of timeless global brands, including Martha Stewart, Laura Ashley, Sur La Table, BCBGMAXAZRIA and Stance. The addition of Roberto Cavalli further strengthens Marquee Brands’ position as a leader in the luxury and lifestyle sectors, bringing total portfolio-wide retail sales to approximately US$5 billion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260520070705/en/
Roberto Cavalli Spring/Summer 2026
“Roberto Cavalli stands as one of luxury’s defining Italian houses, with a bold creative identity and enduring brand ethos,” said Heath Golden, CEO, Marquee Brands. “We see extraordinary potential to build on that foundation through thoughtful brand stewardship and strategic expansion. In partnership with DAMAC, a leader in luxury real estate, we will continue to elevate the Roberto Cavalli experience worldwide.”
Hussain Sajwani, Founder of DAMAC Group, said: “Roberto Cavalli is one of the most distinctive luxury brands in the world. After several years of solidifying the brand’s foundation, we set out to find a strategic partner with the skillset to take the brand to the next level. We are confident Marquee Brands is the right partner to do so. Given our love for the brand and meaningful ongoing shareholdings, we look forward to supporting Marquee Brands’ efforts, by among other things, continuing to expand the Roberto Cavalli lifestyle through branded residences and hospitality projects in premier global destinations, an area that remains fully owned and operated by DAMAC. This collaboration marks an exciting new era for the brand. We look forward to its significant future expansion.”
Marquee Brands, owned by funds managed by Neuberger, a global investment management firm, continues to scale its global platform by acquiring heritage brands with deep consumer resonance. Roberto Cavalli marks the twenty-second brand in Marquee Brands’ portfolio.
“Marquee Brands has established a proven, capital‑efficient business model for driving growth through disciplined brand management, strategic partnerships and a long-term investment horizon,” said Zachary Sigel, Managing Director at Neuberger and Co-Founder of Marquee Brands. “The acquisition of Roberto Cavalli reinforces Neuberger’s confidence in the platform and its ability to continue to create value for investors.”
The partnership between Marquee Brands and DAMAC expands the global reach of the Roberto Cavalli brand, bringing together their complementary strengths and shared commitment to elevating the legendary Italian maison. Marquee Brands will accelerate Roberto Cavalli’s growth by introducing new categories, services and experiential touchpoints across Europe, the United Kingdom, the United States, the Middle East, Asia Pacific and Latin America.
DAMAC will continue to scale the brand’s presence through Roberto Cavalli-branded residences and hospitality projects across key global markets, reinforcing the brand’s luxury position and desirability. The partnership creates a powerful platform that unites Marquee Brands’ expertise in global brand development with DAMAC’s leadership in luxury real estate and hospitality, unlocking significant new opportunities for the future of Roberto Cavalli.
As part of the transaction, Marquee Brands announces Milan-based partner The Level Group (TLG) as its core operating partner. TLG will lead the development, manufacturing and distribution of the brand’s women’s and men’s collections, ensuring a unified and elevated product vision across key markets. In addition, TLG will assume responsibility for retail and e‑commerce operations and wholesale distribution in Europe and the United States, strengthening Roberto Cavalli’s direct-to-consumer presence and global retail strategy.
RBC Capital Markets served as financial advisor and Greenberg Traurig acted as legal advisor to Marquee Brands. BDA Partners served as financial advisor to DAMAC Properties.
ABOUT ROBERTO CAVALLI
Founded in 1970, Roberto Cavalli is a leading Italian brand in fashion, accessories and luxury lifestyle. Defined by a glamorous contemporary aesthetic, the brand is the quintessential expression of Italian excellence, craftsmanship and its Mediterranean origins. The Roberto Cavalli portfolio is positioned within the luxury segment and includes the Home, Junior, Eyewear, Perfumes, Watches and Just Cavalli collections. www.robertocavalli.com
ABOUT MARQUEE BRANDS
Marquee Brands is the premier accelerator of timeless brands, unlocking value and building global influence. With a focus on driving growth and building sustainable brand equity, we partner with best-in-class manufacturers, operators, retailers, and distributors to scale brands across markets and channels. Marquee Brands’ global portfolio spans three distinct platforms: Home & Culinary, Fashion & Lifestyle, Luxury and Active & Outdoor. The portfolio of brands includes Martha Stewart, Laura Ashley, Sur La Table, Emeril Lagasse, America’s Test Kitchen, BCBGMAXAZRIA, BCBG, Ben Sherman, Bruno Magli, Anti Social Social Club, Totes, Isotoner, Destination Maternity, Motherhood, A Pea in the Pod, Stance, Dakine and Body Glove. For more information visit, www.marqueebrands.com.
ABOUT NEUBERGER PRIVATE MARKETS
Neuberger Private Markets is a division of Neuberger and has been an active and successful private markets investor since 1987. Neuberger Private Markets invests across strategies, asset classes, and geographies for a large number of sophisticated and renowned institutions and individuals globally. As of December 31, 2025, Neuberger Private Markets manages over $155 billion of investor commitments across primaries, co-investments, secondaries, private credit, and specialty strategies. Neuberger Private Markets has an experienced and diverse team of over 500 professionals with a global presence in 17 offices globally.
ABOUT DAMAC GROUP
DAMAC Group is a global private business conglomerate founded by Hussain Sajwani in 1982. Starting in catering and logistics, it has expanded into diverse industries, including real estate, hospitality, data centers, fashion, and capital markets. DAMAC Properties is the largest private real estate developer in the UAE and the Middle East, and has been at the forefront of the Middle East’s luxury real estate market since 2002, delivering award-winning residential, commercial and leisure properties across the region and internationally, including in the UAE, Saudi Arabia, Qatar, Jordan, Lebanon, Iraq, the Maldives, Canada, the United States, as well as the United Kingdom. Since then, DAMAC has delivered more than 50,000 homes with over 55,000 more in diverse planning and development phases, joining forces with some of the world’s most eminent fashion and lifestyle brands to create tremendous living experiences, such as Roberto Cavalli and de GRISOGONO. With a consistent vision and momentum, DAMAC is building the next generation of luxury living across the globe. The Group also owns hotel assets under brands such as Radisson, Paramount, and Rotana, with an expanding hospitality portfolio. Beyond real estate, DAMAC is a leader in the data center industry through DAMAC Digital and has acquired luxury brands Roberto Cavalli and de GRISOGONO. Through DAMAC Capital, it invests in future-focused industries like tech, finance, and life sciences. Committed to social impact, the Hussain Sajwani – DAMAC Foundation supports education, innovation, and community-driven initiatives. For more information visit, www.damacgroup.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260520070705/en/
Contacts
For media inquiries, contact the Marquee Brands Press Office:
Email: corporate@marqueebrands.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom